Popular on Amzeal
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Retrospec Appoints Nick Marvik as New Head of Growth to Lead eCommerce Expansion
- Connected Technologies Delivers Cutting-Edge Technology to Landmark Properties' Student Housing Communities
- AI pioneer & tech icon, Professor Chris Imafidon speaks on President Trump's $500 Billion AI project
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil
- How Technology is Making the Florida Court System More Accessible
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- The Power Of Online Reviews & Why They Matter
- Osaretin Agbonavbare's AI NGO Makes History at Trump's Presidential Inauguration Ceremony
- Mayo Clinic emergency medicine physician, AI expert highlight international healthcare conference
Similar on Amzeal
- Atlanta Students to Talk with Astronauts on International Space Station
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
- NC Health Official Urges Ban on Wilderness Therapy Camps Following Child's Death
- IMCAS 2025: Leger presents innovation in cellulite treatment and gluteal harmonization in Paris
- $27 Million Funding; Coverage on Sanjay Gupta/CNN for Treatment of Suicidal Depression; Nasdaq Tier Uplisting: NRx Pharmaceuticals: Stock Symbol: NRXP
- Performentor, LLC Announces 2025 Unleash People Energy® Award Winners
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil
IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease
Amzeal News/10568321
IVIEW Therapeutics Inc., a clinical stage biotechnology company advancing innovative treatments for ocular diseases, proudly announces the dosing of the first patient in the Phase 1/2 clinical trial of IVW-1001 Ophthalmic Eyelid Wipe. This milestone marks the initiation of the clinical evaluation of IVW-1001, a novel TRPM8 agonist designed to treat signs and symptoms of dry eye disease.
CRANBURY, N.J. - Amzeal -- The commencement of patient dosing in the Phase 1/2 trial represents a significant advancement in IVIEW Therapeutics' mission to develop innovative solutions for individuals suffering from dry eye disease, particularly those inadequately managed by artificial tears. This first-in-human (FIH) trial aims to rigorously assess the safety, tolerability, and preliminary efficacy of IVW-1001.
Dry eye disease is a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics, offers promising potential as a therapeutic intervention through its TRPM8 agonist mechanism, targeting the underlying causes of dry eye. The innovative delivery route via an ophthalmic eyelid wipe further distinguishes IVW-1001 as a potentially groundbreaking treatment.
More on Amzeal News
Houman Hemmati, MD, PhD, Chief Medical Advisor, leading the clinical development of the IVW-1001 program, stated, "Dosing the first patient in our Phase 1/2 clinical trial is an exciting and critical step forward. Our focus remains on thoroughly evaluating the safety and potential efficacy of IVW-1001. This investigational TRPM8 agonist offers an innovative approach to treating dry eye diseases, and we are committed to advancing this program to address the unmet needs of patients worldwide."
Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., added, "We are thrilled to initiate the clinical development of IVW-1001 with the dosing of our first patient. This milestone underscores our commitment to pioneering treatments for dry eye diseases and highlights the potential of our novel TRPM8 activation mechanism. We look forward to the progress of this trial and the insights it will provide."
About IVIEW Therapeutics Inc.
More on Amzeal News
IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. IVIEW is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company's website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com
Dry eye disease is a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics, offers promising potential as a therapeutic intervention through its TRPM8 agonist mechanism, targeting the underlying causes of dry eye. The innovative delivery route via an ophthalmic eyelid wipe further distinguishes IVW-1001 as a potentially groundbreaking treatment.
More on Amzeal News
- OEM Technology Partnerships Launches Brokerage Specializing in 100+ OEM Technologies
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- G2 Names OpenWater a Winter 2025 Leader in Awards and Scholarship Management
- Zezgo Rent A Car has arrived In Cyprus to Improve Car Rental Options
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
Houman Hemmati, MD, PhD, Chief Medical Advisor, leading the clinical development of the IVW-1001 program, stated, "Dosing the first patient in our Phase 1/2 clinical trial is an exciting and critical step forward. Our focus remains on thoroughly evaluating the safety and potential efficacy of IVW-1001. This investigational TRPM8 agonist offers an innovative approach to treating dry eye diseases, and we are committed to advancing this program to address the unmet needs of patients worldwide."
Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., added, "We are thrilled to initiate the clinical development of IVW-1001 with the dosing of our first patient. This milestone underscores our commitment to pioneering treatments for dry eye diseases and highlights the potential of our novel TRPM8 activation mechanism. We look forward to the progress of this trial and the insights it will provide."
About IVIEW Therapeutics Inc.
More on Amzeal News
- Kim Estes Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Andre Kay Honored with Black Excellence Award by the Florida Panthers
- Media Advisory Pastor Mark Burns to Deliver Remarks at BEYA Stars and Stripes Dinner What: The BEYA Stars and Stripes
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. IVIEW is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company's website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com
Source: IVIEW Therapeutics Inc.
0 Comments
Latest on Amzeal News
- Uhland Pop Shop Launches February 11, 2025, Bringing Local Pride to Uhland, TX
- Nova Health Labs Welcomes New Advisory Board Members to Drive Patient-Centered Innovation
- C-BATT joins NAATBatt, the premier US Battery Trade Association
- Partnerships to Launch Digital Entertainment Hub in China; $40 Million Investment into Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- Sip Social Co. Brings Refreshing Energy to the Miami Marathon Finish Festival with FP Movement
- Igniting Souls® and EOS Worldwide® Launch EOS Impact™: The Exclusive Publishing Collaboration for 850+ EOS Implementers
- Ceramic Liberty Unveils CL8Y: A Revolutionary Deflationary Memecoin Set to Redefine DeFi
- International Women's Day Gala to Celebrate Women's Achievements and Support Fire Survivors
- Sidow Sobrino Unleashes Bite After Bite, a Captivating Music Video & Song from His 12th Studio Album, Seminal
- How New U.S. Tariffs Are Reshaping the Frequency Control & Precision Timing Industry
- L-Tron welcomes Senator Pam Helming to their Victor, NY Office
- PCnet Supports Business Growth with Reliable Managed IT Services
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Atlanta Students to Talk with Astronauts on International Space Station
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- All me - secure anonymous social - kickstarter crowdfunding
- HomeFortis Launches Target Hardening Guides for Home Security
- Retired Leadership Facilitator Shares Decades of Wisdom in New Book
- CCG Relaunches Spring Virtual Recruitment Fair to Connect Employers with Top STEM, AI, and Veteran Talent
- The AI Revolution: How ChatGPT-Like Tools Will Transform Industries by 2030